These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23278519)

  • 1. Benchmark dose profiles for joint-action quantal data in quantitative risk assessment.
    Deutsch RC; Piegorsch WW
    Biometrics; 2012 Dec; 68(4):1313-22. PubMed ID: 23278519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benchmark dose profiles for joint-action continuous data in quantitative risk assessment.
    Deutsch RC; Piegorsch WW
    Biom J; 2013 Sep; 55(5):741-54. PubMed ID: 23852573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Web-Based System for Bayesian Benchmark Dose Estimation.
    Shao K; Shapiro AJ
    Environ Health Perspect; 2018 Jan; 126(1):017002. PubMed ID: 29329100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
    Sand S; Victorin K; Filipsson AF
    J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD).
    Gaylor DW; Aylward LL
    Regul Toxicol Pharmacol; 2004 Aug; 40(1):9-17. PubMed ID: 15265602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benchmark Dose Analysis via Nonparametric Regression Modeling.
    Piegorsch WW; Xiong H; Bhattacharya RN; Lin L
    Risk Anal; 2014 Jan; 34(1):135-51. PubMed ID: 23683057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model Selection and Estimation with Quantal-Response Data in Benchmark Risk Assessment.
    Peña EA; Wu W; Piegorsch W; West RW; An L
    Risk Anal; 2017 Apr; 37(4):716-732. PubMed ID: 27322778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the benchmark dose method for dichotomous data: model dependence and model selection.
    Sand S; Filipsson AF; Victorin K
    Regul Toxicol Pharmacol; 2002 Oct; 36(2):184-97. PubMed ID: 12460753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Information-theoretic model-averaged benchmark dose analysis in environmental risk assessment.
    Piegorsch WW; An L; Wickens AA; West RW; Peña EA; Wu W
    Environmetrics; 2013 May; 24(3):143-157. PubMed ID: 24039461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benchmark dose calculation for ordered categorical responses.
    Chen CC; Chen JJ
    Risk Anal; 2014 Aug; 34(8):1435-47. PubMed ID: 24444309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model Uncertainty and Bayesian Model Averaged Benchmark Dose Estimation for Continuous Data.
    Shao K; Gift JS
    Risk Anal; 2014 Jan; 34(1):101-20. PubMed ID: 23758102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application and advance of benchmark dose on risk assessment].
    Tian L; Lu XT; Jin TY
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2004 Aug; 22(4):290-2. PubMed ID: 15355717
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of available benchmark dose softwares and models using trichloroethylene as a model substance.
    Falk Filipsson A; Victorin K
    Regul Toxicol Pharmacol; 2003 Jun; 37(3):343-55. PubMed ID: 12758215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
    Davis JA; Gift JS; Zhao QJ
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A general theory of effect size, and its consequences for defining the benchmark response (BMR) for continuous endpoints.
    Slob W
    Crit Rev Toxicol; 2017 Apr; 47(4):342-351. PubMed ID: 27805866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian model-averaged benchmark dose analysis via reparameterized quantal-response models.
    Fang Q; Piegorsch WW; Simmons SJ; Li X; Chen C; Wang Y
    Biometrics; 2015 Dec; 71(4):1168-75. PubMed ID: 26102570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing dose-response: I: Critical assessment of the benchmark dose concept.
    Murrell JA; Portier CJ; Morris RW
    Risk Anal; 1998 Feb; 18(1):13-26. PubMed ID: 9523441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a critical dose level for risk assessment: developments in benchmark dose analysis of continuous endpoints.
    Sand S; von Rosen D; Victorin K; Filipsson AF
    Toxicol Sci; 2006 Mar; 90(1):241-51. PubMed ID: 16322076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.